Comparative Pharmacology
Head-to-head clinical analysis: NICOTINE POLACRILEX ORAL versus NICOTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICOTINE POLACRILEX ORAL versus NICOTROL.
NICOTINE POLACRILEX vs NICOTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine polacrilex acts as a nicotinic acetylcholine receptor agonist, binding to α4β2 receptors in the ventral tegmental area and mediating dopamine release in the nucleus accumbens, which reduces withdrawal symptoms and cravings by providing a lower and slower peak of nicotine compared to smoking.
Nicotine is a nicotinic acetylcholine receptor agonist. It binds to and activates nicotinic acetylcholine receptors in the brain, leading to dopamine release and other neurotransmitter effects that mediate nicotine dependence and withdrawal symptoms.
2 mg or 4 mg lozenge or gum as needed up to 20 lozenges or pieces of gum per day; typical dosing: 1 lozenge or piece of gum every 1-2 hours while awake, up to 12 per day. For smoking cessation, initial dose based on smoking habits: if first cigarette within 30 minutes of waking, use 4 mg; if >30 minutes, use 2 mg.
Inhalation: 1 cartridge (4 mg) inhaled as needed for craving relief, up to 16 cartridges per day; typical initial dose: 4-8 cartridges per day, with weaning over 12 weeks.
None Documented
None Documented
The terminal elimination half-life of nicotine is approximately 2 hours (range 1-4 hours) after intravenous administration or smoking, but after polacrilex gum use, absorption is slower and half-life may be slightly prolonged due to continued absorption. Clinical context: short half-life necessitates frequent dosing to maintain levels for smoking cessation.
2 hours (range 1-4 h). Shorter in smokers due to induction of metabolism; prolonged in renal impairment.
Nicotine and its metabolites are primarily excreted renally. About 10-20% of nicotine is excreted unchanged in urine, with the remainder as metabolites, mainly cotinine. Urinary pH affects excretion; acidic urine increases clearance. Biliary/fecal excretion is negligible (<5%).
Primarily renal (10-20% unchanged; 80-90% as metabolites, mainly cotinine and nicotine-N'-oxide). Biliary/fecal excretion accounts for <10%.
Category C
Category C
Smoking cessation aid
Smoking cessation aid